Walvax Biotechnology Co.Ltd(300142) 3 on the evening of March 18, the annual report of 2021 was released, and the company achieved an operating revenue of 3.463 billion yuan in 2021, with a year-on-year increase of 17.82%; The net profit attributable to the shareholders of the listed company was 428 million yuan, a year-on-year decrease of 57.36%. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 591 million yuan, a year-on-year decrease of 17.33%; The basic earnings per share is 0.27 yuan. The company plans to distribute a cash dividend of 0.27 yuan (including tax) to all shareholders for every 10 shares. On the same day, the company announced that it planned to use its own funds to buy back the company’s shares, the repurchase price would not exceed 70 yuan / share, and the expected repurchase amount would not exceed 420 million yuan.
As for the growth of revenue, Walvax Biotechnology Co.Ltd(300142) said that it was mainly because the company continued to strengthen the expansion of vaccine market and strengthen marketing management. The sales revenue of the company’s heavy product 13 price pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as “13 price pneumonia conjugate vaccine”) increased significantly compared with the same period of last year. The annual report shows that in 2021, Yuxi Watson 13 valent pneumonia conjugate vaccine, a Walvax Biotechnology Co.Ltd(300142) subsidiary, was approved and issued 4.9508 million doses, an increase of 10.88% over the same period of last year, and the sales revenue increased by 65.59% over the same period of last year.
In April 2021, Yuxi Watson reached cooperation with marocvax SARL of Morocco, and signed an exclusive distribution agreement on the finished product import, distribution, sales and stock solution supply cooperation business of 13 valent pneumonia conjugate vaccine produced by Yuxi Watson in Morocco. At present, the 13 valent pneumonia conjugate vaccine has obtained the marketing license in Morocco and completed its registration in Morocco.
During the reporting period, the company made every effort to promote the research and industrialization progress of all products under research in the stage of clinical research and industrialization. Bivalent HPV vaccine has completed the verification of clinical trial site and production site, and was included in the list of priority review varieties in July 2021. At present, the relevant review and approval of bivalent HPV vaccine application for production is in progress. Nine valent HPV vaccine is carrying out various preliminary preparations for phase III clinical research. The COVID-19 mRNA vaccine, recombinant New Coronavirus vaccine (chimpanzee adenovirus vector), which was jointly developed by the company and its partners, received the drug clinical trial approval approved by the State Food and Drug Administration in June 2020 and May 2021 respectively. At present, the COVID-19 mRNA vaccine is in phase III clinical research stage, and the recombinant New Coronavirus vaccine (chimpanzee adenovirus vector) is in phase II clinical research stage. The recombinant New Coronavirus vaccine (CHO cell), a subsidiary of Shanghai Ze run, was awarded the “drug clinical trial approval” in June 2021, and is now in phase II clinical research. The work of the above 3 COVID-19 vaccine clinical trials is continuing to advance according to plan.
Walvax Biotechnology Co.Ltd(300142) said that the decline in net profit in 2021 was due to the company’s increasing investment in R & D of new products and projects and actively promoting clinical trials of key R & D projects in China and abroad. The annual report shows that from 2019 to 2021, Walvax Biotechnology Co.Ltd(300142) the R & D investment was 258 million yuan, 316 million yuan and 754 million yuan respectively, of which the R & D investment in 2021 increased by 138.68% over the same period of the previous year. In 2021, the company’s R & D expenses were 621 million yuan, which had a certain erosion on profits. On the other hand, the stock price of Jiahe biological pharmaceutical (Cayman) Holding Co., Ltd. held by the company fell sharply at the end of the period, resulting in the loss of changes in fair value during the reporting period.
On the same day, the company announced that in order to promote the healthy, stable and long-term development of the company, safeguard the interests of the majority of shareholders, enhance investor confidence, and improve the company’s long-term incentive mechanism, Walvax Biotechnology Co.Ltd(300142) plans to use its own funds to repurchase the company’s shares for the implementation of the employee stock ownership plan or stock incentive plan. The upper limit of repurchase is 6 million shares, the lower limit of repurchase is 3 million shares, and the repurchase price does not exceed 70 yuan / share, It is estimated that the repurchase amount will not exceed 420 million yuan.
